Question explored with the scientific record
amitryptalin
Amitriptyline works for some conditions, but the evidence for it is older, industry-funded, and often compared to placebo rather than to a no-treatment group.
The retrieved studies show amitriptyline is used for depression, migraine prevention, fibromyalgia, and cyclic vomiting syndrome. A large 2018 network meta-analysis of 522 trials found all antidepressants, including amitriptyline, beat placebo on depression scales [1]. But 409 of those trials were funded by drug companies [1]. For pediatric migraine, the 2017 CHAMP trial (361 children) found amitriptyline no better than placebo at cutting headache days, and it caused more fatigue and dry mouth [4]. A 2020 overview of systematic reviews for fibromyalgia rated the evidence for amitriptyline's effect on pain as low, though moderate for sleep and fatigue [5].
The harms are real. A single 50 mg dose in older adults caused severe cognitive impairment: slower reaction times, fewer correct detections, and far more false alarms on vigilance tests compared to placebo [6]. In a 12-week depression trial, amitriptyline raised heart rate by 17 beats per minute on average [3]. The drug also increased lipoprotein(a), a cardiovascular risk marker, though the change was not statistically significant in a small 35-patient study [2].
| Condition | What the evidence shows | Key limitation |
|---|---|---|
| Depression | More effective than placebo on rating scales [1] | Mostly industry-funded; no long-term hard outcomes |
| Pediatric migraine | No better than placebo [4] | High placebo response; more side effects |
| Fibromyalgia | Low evidence for pain; moderate for sleep [5] | Small, older trials |
| Cognitive effects (single dose) | Significant impairment in older adults [6] | Acute study only |
My call: amitriptyline can reduce symptom scores in depression and improve sleep in fibromyalgia, but the evidence is thin, old, and industry-linked. For pediatric migraine, it does not work. The cognitive and cardiovascular side effects are not trivial. Confidence: moderate for depression benefit, high for no benefit in pediatric migraine.
Sources used 6
-
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
This systematic review and network meta-analysis evaluates the efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder, finding that all antidepressants are more effective than placebo, with varying levels of accepta…
DOI: 10.1016/S0140-6736(17)32802-7 -
Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression
This study investigates the effects of paroxetine and amitriptyline on lipoprotein(a) levels in patients with major depression, finding that paroxetine significantly lowers these levels, potentially reducing vascular mortality risk.
DOI: 10.1177/0269881110382469 -
The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo
A 12-week, double-blind, randomized trial in general practice comparing L-tryptophan, amitriptyline, their combination, and placebo for depression, finding all active treatments more effective than placebo (with the combination most effective), along with safety and pharmacokine…
DOI: 10.1017/s0033291700049047 -
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine
The CHAMP trial found that neither amitriptyline nor topiramate was more effective than placebo in reducing headache frequency in children and adolescents with migraines over a 24-week period, with both medications associated with higher rates of adverse events.
DOI: 10.1056/NEJMoa1610384 -
Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews
An overview of systematic reviews comparing duloxetine and amitriptyline for fibromyalgia in adults, finding duloxetine's benefits mainly for mood disorders and older patients' safety, while amitriptyline showed evidence of benefit for sleep, fatigue, and quality of life in some…
DOI: 10.1186/s42358-020-00137-5 -
Cognitive Performance in Geriatric Subjects after Acute Treatment with Antidepressants
A double-blind, crossover study in 15 geriatric adults comparing the acute cognitive effects of trazodone (100 mg), amitriptyline (50 mg), and placebo across tasks measuring divided attention, tracking, visual processing speed, and vigilance, finding amitriptyline causes broader…
DOI: 10.1159/000118285